Case Reports
doi: 10.1007/BF00410649.
Hepatic failure in a patient treated with dacarbazine (DTIC) for malignant melanoma
- PMID: 528568
- PMCID: PMC12252948
- DOI: 10.1007/BF00410649
Item in Clipboard
Case Reports
Hepatic failure in a patient treated with dacarbazine (DTIC) for malignant melanoma
J Cancer Res Clin Oncol.
1979.
Abstract
A 55-year-old white woman received chemotherapy with DTIC after surgery for malignant melanoma (stage I, SSM IV, depth of invasion 12 mm). She died suddenly during the second treatment cycle. Autopsy revealed massive necrosis of the liver and thrombosis of the hepatic veins. The cause of the fatal outcome is attributed to the adverse toxic effects of DTIC.
Similar articles
-
[Dacarbazine in malignant melanoma. Rare, severe side-effect: Budd-Chiari-syndrome (author's transl)].Z Hautkr. 1982 Jul 1;57(13):971-80. Z Hautkr. 1982. PMID: 7113323 German.
-
[Budd-Chiari syndrome following dacarbazine therapy of malignant melanoma--an avoidable complication?].Z Hautkr. 1985 Jun 15;60(12):961-72. Z Hautkr. 1985. PMID: 4024678 German.
-
Fatal hepatic vascular toxicity of DTIC. Is it really a rare event?Cancer. 1988 May 15;61(10):1988-91. doi: 10.1002/1097-0142(19880515)61:10<1988::aid-cncr2820611010>3.0.co;2-5. Cancer. 1988. PMID: 3359400
-
Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2.J Dermatolog Treat. 2014 Oct;25(5):401-8. doi: 10.3109/09546634.2013.813897. Epub 2013 Jul 3. J Dermatolog Treat. 2014. PMID: 23763243
-
Interferon alpha for the adjuvant treatment of cutaneous melanoma.Cochrane Database Syst Rev. 2013 Jun 18;2013(6):CD008955. doi: 10.1002/14651858.CD008955.pub2. Cochrane Database Syst Rev. 2013. PMID: 23775773 Free PMC article.
Cited by
-
Drug effects on the liver. An updated tabular compilation of drugs and drug-related hepatic diseases.Dig Dis Sci. 1983 Jul;28(7):651-66. doi: 10.1007/BF01299927. Dig Dis Sci. 1983. PMID: 6305608 Review.
-
Current status and perspectives in immunotherapy for metastatic melanoma.Oncotarget. 2018 Jan 3;9(15):12452-12470. doi: 10.18632/oncotarget.23746. eCollection 2018 Feb 23. Oncotarget. 2018. PMID: 29552325 Free PMC article. Review.
-
DTIC (dacarbazine)-induced hepatic damage. Possible pathogenesis and prevention.Arch Dermatol Res. 1981;270(3):375-6. doi: 10.1007/BF00403944. Arch Dermatol Res. 1981. PMID: 6115618 No abstract available.
-
Clinical management of cytotoxic drug overdose.Med Toxicol Adverse Drug Exp. 1988 Jul-Aug;3(4):253-63. doi: 10.1007/BF03259938. Med Toxicol Adverse Drug Exp. 1988. PMID: 3054425 Review.
-
A single-center experience in radioembolization as salvage therapy of hepatic metastases of uveal melanoma.Acta Radiol Open. 2015 Apr 6;4(4):2047981615570417. doi: 10.1177/2047981615570417. eCollection 2015 Apr. Acta Radiol Open. 2015. PMID: 25922690 Free PMC article.
References
-
- Baird, G.M., Willoughby, M.L.N.: Photodegradation of dacarbazine. Lancet 1978/23, 681 - PubMed
-
- Costanza, M.E., Nathanson, L., Schoenfeld, D., Wolter, J., Colsky, J., Regelson, W, Cunningham, T., Sedransk, N.: Results with methyl-CCNU and DTIC in metastatic melanoma. Cancer 40, 1010–1015 (1977) - PubMed
-
- Griner, P.F., Elbadawi, A., Packman, C.H.: Veno-occlusive disease of the liver after chemotherapy of acute leukemia. Report of two cases. Ann. Intern. Med. 85, 578–582 (1976) - PubMed
-
- Johnson, R.O., Metter, G., Wilson, W., Hill, G., Krementz, E.: Phase I evaluation of DTIC (NSC-45388) and other studies in malignant melanoma in the central oncology group. Cancer Treatm. Rep. 60, 183–187 (1976) - PubMed
-
- Lehrner, L.M., Enck, R.E.: Hepatic vein thrombosis after chemotherapy for histiocytoma. Ann. Intern. Med. 88, 575–576 (1978) - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources